Urology News and Research

Latest Urology News and Research

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.

29 Oct 2009

Urigen Pharmaceuticals announces a presentation on interstitial cystitis/painful bladder syndrome

Urigen Pharmaceuticals, Inc., focused on the development of treatments for urologic disorders and pain, announces a presentation at its offices on October 30, 2009 at 2PM PST. The slides presented will be posted to its website at www.urigen.com after the close of trading that day.

28 Oct 2009

FDA issues clearance for Lumenis' PolyScope Flexible Endoscope

Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced that on September 30th, 2009 the FDA issued a 510K to Lumenis stating that the PolyScope Flexible Endoscope can now be sold in the United States.

From Lumenis Inc. 28 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

Teleflex's revenues decreases to $461.5 million in third quarter 2009

Teleflex Incorporated today announced financial results for the Third Quarter ended September 27, 2009.

27 Oct 2009

ACC's initiative for health care reform

As lawmakers debate health care reform, business innovator Lou Weisbach and Clinton White House health care advisor Dr. Richard Boxer are available for interviews to discuss a glaring, missing element of the forthcoming health care legislation: reducing health care costs -- and saving lives -- by preventing and curing disease.

27 Oct 2009

Dartmouth explores glucorticoid side effects on bladder-cancer patients

In her most recent study of possible triggers of cancer among northern New England residents, Dartmouth epidemiologist Margaret R. Karagas, Ph.D., and her team identified an enhanced risk to the bladders of patients taking drugs that suppress the immune system.

27 Oct 2009

NCI funds new Center on Microenvironment and Metastasis to research on cancer

Adding potent research firepower and fresh physical perspectives to combat cancer, the National Cancer Institute (NCI) has funded the new Center on the Microenvironment and Metastasis, which will be headquartered at Cornell University.

27 Oct 2009

Study links urogenital birth defects with DDT

Women who lived in villages sprayed with DDT to reduce malaria gave birth to 33 per cent more baby boys with urogenital birth defects (UGBD) between 2004 and 2006 than women in unsprayed villages, according to research published online by the UK-based urology journal BJUI.

24 Oct 2009

DDT exposure is associated with urogenital birth defects in newborn boys

23 Oct 2009

Sectra signs distribution agreement with Attieh Medico

The Swedish IT and medical-technology company Sectra has signed a distribution agreement with Attieh Medico, a leading medical technology company in the Kingdom of Saudi Arabia.

22 Oct 2009

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized renal cell carcinoma (kidney cancer).

21 Oct 2009

MIRP surgery carries higher risk of impotence and incontinence than traditional surgery

A new study debating the effectiveness of minimally invasive prostate surgery is not telling the whole story, warns Dr. David B. Samadi, Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology at The Mount Sinai Medical Center in New York.

21 Oct 2009

New tools needed to identify men and women at risk for the most aggressive cancers

Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."

21 Oct 2009

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.

21 Oct 2009

Eclipsys' 2009 Circle of Excellence Award winners announced

Eclipsys Corporation®, The Outcomes Company®, today announced the winners of its 2009 Circle of Excellence Award program.

21 Oct 2009

Testicular cancer survivors at risk of effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

20 Oct 2009

Study explores the link between LUTS and depression, anxiety disorders, sexual trauma

Depression, anxiety disorders and sexual trauma have all been implicated as risk factors in lower urinary tract symptoms (LUTS) such as incontinence and overactive bladder.

20 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009